Olema Pharmaceuticals, Inc. (OLMA)
NASDAQ: OLMA · Real-Time Price · USD
14.59
-0.70 (-4.58%)
At close: Apr 28, 2026, 4:00 PM EDT
14.61
+0.02 (0.14%)
After-hours: Apr 28, 2026, 7:44 PM EDT
Olema Pharmaceuticals Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Olema Pharmaceuticals stock have an average target of 44.89, with a low estimate of 27 and a high estimate of 62. The average target predicts an increase of 207.68% from the current stock price of 14.59.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 19, 2026.
Analyst Ratings
The average analyst rating for Olema Pharmaceuticals stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 6 | 7 | 7 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 7 | 8 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wolfe Research | Wolfe Research | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Mar 27, 2026 |
| Jefferies | Jefferies | Strong Buy Initiates $43 → $40 | Strong Buy | Initiates | $43 → $40 | +174.16% | Mar 19, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $55 → $58 | Buy | Maintains | $55 → $58 | +297.53% | Mar 18, 2026 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $38 → $27 | Strong Buy | Maintains | $38 → $27 | +85.06% | Mar 18, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $60 → $62 | Strong Buy | Maintains | $60 → $62 | +324.95% | Mar 17, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
25.91M
EPS This Year
-2.30
from -1.87
EPS Next Year
-2.55
from -2.30
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 52.5M | ||||||
| Avg | n/a | 25.9M | ||||||
| Low | n/a | 2.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -2.00 | -1.84 | |||
| Avg | -2.30 | -2.55 | |||
| Low | -2.70 | -3.51 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.